News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,246 Results
Type
Article (13873)
Company Profile (294)
Press Release (246079)
Section
Business (79324)
Career Advice (148)
Deals (13179)
Drug Delivery (32)
Drug Development (50294)
Employer Resources (31)
FDA (5669)
Job Trends (5112)
News (144065)
Policy (10013)
Tag
Academia (901)
Alliances (21466)
Alzheimer's disease (736)
Approvals (5643)
Artificial intelligence (63)
Bankruptcy (97)
Best Places to Work (4497)
Biotechnology (242)
Breast cancer (65)
Cancer (695)
Cardiovascular disease (62)
Career advice (129)
CAR-T (56)
Cell therapy (175)
Clinical research (39808)
Collaboration (238)
Compensation (97)
COVID-19 (1002)
C-suite (68)
Cystic fibrosis (66)
Data (792)
Diabetes (73)
Diagnostics (1200)
Earnings (28977)
Events (46830)
Executive appointments (192)
FDA (5958)
Funding (243)
Gene editing (55)
Gene therapy (145)
GLP-1 (300)
Government (1063)
Healthcare (6531)
Infectious disease (1036)
Inflammatory bowel disease (94)
IPO (7177)
Job creations (859)
Job search strategy (125)
Layoffs (184)
Legal (1373)
Lung cancer (113)
Manufacturing (74)
Medical device (2552)
Medtech (2553)
Mergers & acquisitions (6099)
Metabolic disorders (223)
Neuroscience (946)
NextGen Class of 2024 (1998)
Non-profit (843)
Northern California (946)
Obesity (122)
Opinion (91)
Parkinson's disease (61)
Patents (51)
People (24975)
Pharmaceutical (49)
Phase I (14002)
Phase II (18516)
Phase III (11740)
Pipeline (320)
Postmarket research (846)
Preclinical (5922)
Radiopharmaceuticals (205)
Rare diseases (167)
Real estate (1409)
Regulatory (8201)
Research institute (930)
Southern California (865)
Startups (1963)
United States (7580)
Vaccines (159)
Weight loss (76)
Date
Today (71)
Last 7 days (500)
Last 30 days (2268)
Last 365 days (20689)
2024 (18966)
2023 (22415)
2022 (26826)
2021 (27807)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16829)
Australia (2837)
California (2142)
Canada (710)
China (163)
Colorado (79)
Connecticut (84)
Europe (36238)
Florida (226)
Georgia (62)
Illinois (125)
Indiana (54)
Kansas (55)
Maryland (298)
Massachusetts (1699)
Michigan (48)
Minnesota (93)
New Jersey (542)
New York (608)
North Carolina (398)
Northern California (946)
Ohio (78)
Pennsylvania (426)
South America (207)
Southern California (865)
Texas (226)
Washington State (217)
260,246 Results for "mirati therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. ® (“Mirati”).
January 23, 2024
·
4 min read
Business
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Bristol Myers Squibb and Mirati Therapeutics, Inc.® announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Mirati for $58.00 per share in cash, for a total equity value of $4.8 billion.
October 8, 2023
·
22 min read
Business
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.
November 6, 2023
·
14 min read
Business
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer
Mirati Therapeutics, Inc.®, a commercial stage biotechnology company, announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.
August 23, 2023
·
3 min read
Biotech Beach
Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek
Mirati Therapeutics, Inc.®, a commercial stage biotechnology company announced that David Meek and the Company mutually agreed for Mr. Meek to step down from his role as CEO and as a member of the Board of Directors.
August 8, 2023
·
4 min read
Deals
Sanofi Mulls Mirati Buy as KRAS Battle Heats Up: Bloomberg
Following a Phase III failure and the departure of its CEO, Mirati Therapeutics is rumored to be engaged in acquisition discussions with French pharma giant Sanofi, according to Bloomberg.
October 6, 2023
·
2 min read
·
Tristan Manalac
Biotech Beach
Mirati To Present Updated Clinical Data at ESMO Congress 2023
Mirati Therapeutics, Inc.® announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain.
September 27, 2023
·
5 min read
Biotech Beach
Mirati Therapeutics Announces Proposed Public Offering - August 08, 2023
Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced that it intends to offer and sell $250.0 million of shares of its common stock, and, to certain investors, pre-funded warrants to purchase shares of common stock, in an underwritten public offering.
August 8, 2023
·
3 min read
Business
Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the second quarter 2023 along with recent pipeline and corporate updates.
August 8, 2023
·
13 min read
Deals
BMS Buys Mirati for $4.8B to Boost Cancer Business
Following rumors last week of a potential acquisition by Sanofi, Bristol Myers Squibb on Sunday announced that it paid $4.8 billion to gain access to Mirati Therapeutics’ oncology-focused portfolio.
October 9, 2023
·
2 min read
·
Tristan Manalac
1 of 26,025
Next
